HHS-NIH11 · uncategorized
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact...
Deadline
2027-01-07
Funding range
Not listed
Days remaining
90 days
Cost-sharing required
No
Who can apply
- nonprofits_non_higher_education_without_501c3
- county_governments
- small_businesses
- independent_school_districts
- other
- public_and_state_institutions_of_higher_education
- state_governments
- nonprofits_non_higher_education_with_501c3
- public_and_indian_housing_authorities
- city_or_township_governments
- other_native_american_tribal_organizations
- private_institutions_of_higher_education
- for_profit_organizations_other_than_small_businesses
- special_district_governments
- federally_recognized_native_american_tribal_governments
General screening signals
These automated scores use broad defaults. They do not know your organization and are not an eligibility determination or recommendation to apply.
- · Applicant and source gates score 10/100.
- · Mission evidence scores 0/100 for education, youth, community.
- · Geographic fit scores 80/100; restrictions still require notice review.
- · Funding and organizational-capacity fit scores 45/100.
- · Deadline urgency scores 45/100 with 89 days remaining.
- · Application burden appears low.
Plan your application
Keep this notice beside your working checklist
Download the complete official notice and its amendments, then organize your own review in NOFO Workspace. Keep exact source excerpts beside your tasks and notes.
The workspace uses the documents you import. This directory summary does not replace the full notice, its linked guides or agency instructions.